Last reviewed · How we verify
AEGR-733 and ezetimibe — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
AEGR-733 and ezetimibe (AEGR-733 and ezetimibe) — Aegerion Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AEGR-733 and ezetimibe TARGET | AEGR-733 and ezetimibe | Aegerion Pharmaceuticals, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AEGR-733 and ezetimibe CI watch — RSS
- AEGR-733 and ezetimibe CI watch — Atom
- AEGR-733 and ezetimibe CI watch — JSON
- AEGR-733 and ezetimibe alone — RSS
Cite this brief
Drug Landscape (2026). AEGR-733 and ezetimibe — Competitive Intelligence Brief. https://druglandscape.com/ci/aegr-733-and-ezetimibe. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab